Abstract. liver cirrhosis is frequently accompanied by malnutrition and hypoalbuminemia, which in turn commonly induces ascites in patients with liver cirrhosis. ascites leads to abdominal distention and appetite loss, resulting in a deteriorated quality of life (Qol). administration of branched-chain amino acid (Bcaa)-rich supplements reduces hepatic encephalopathy and malnutrition. in addition, Bcaas by themselves up-regulate albumin synthesis through an increase in Fisher's ratio. Thus, in patients with liver cirrhosis, Bcaa-rich supplements seem to be effective at reducing ascites and improving the Qol. Here, we report the case of a 58-year-old Japanese man with liver cirrhosis with severe ascites and peripheral edema. The hepatic function of the patient was classified as Child-Pugh grade C. To reduce protein-energy malnutrition, Bcaa-rich supplements were administered as a late evening snack as part of a regimen including 2000 kcal/day (32.5 kcal/kg/day) of total energy and 83.5 g/day (1.3 g/kg/day) of total protein intake. eight weeks after admission, ascites and edema had decreased. nutritional status also improved from the time of admission to discharge; the serum BCAA level increased from 365.4 to 450.2 µmol/l. Furthermore, the ratio of Bcaas to tyrosine (BTr) increased from 1.70 to 3.65. We also evaluated the effects of nutritional therapy on the patient's Qol using the Medical outcomes Study 36-item Short-Form Health Survey upon admission and at discharge. all subscores showed marked improvement and reached a level greater than the Japanese norm with nutritional treatment. in conclusion, Bcaa supplementation not only reduced ascites, but also improved the Qol in a patient with liver cirrhosis.
Introduction
liver cirrhosis is frequently accompanied by malnutrition and hypoalbuminemia (1, 2) . Hypoalbuminemia is closely associated with the development of ascites in patients with liver cirrhosis (1) . ascites induces abdominal distension and anorexia, leading to increased hypoalbuminemia as well as to a reduced quality of life (Qol) (1) . at present, diuretic agents and the infusion of albumin are the only palliative treatment for ascites. However, these therapies do not up-regulate endogenous albumin synthesis.
The administration of branched-chain amino acid (Bcaa)-rich supplements reduces hepatic encephalopathy (3) (4) (5) . recently, branched-chain amino acid (Bcaa) supplementation was shown to improve nutritional status (6) . decreases in the ratio of Bcaas to aromatic amino acids (aaas) (Fisher's ratio) are associated with the severity of liver disease. Bcaarich supplements up-regulate albumin synthesis through an increase in Fisher's ratio (7) . Thus, in patients with liver cirrhosis, Bcaa supplementation seems to be effective at reducing ascites and improving Qol.
Here, we report a case of Bcaa supplementation that reduced ascites and improved the Qol in a patient with liver cirrhosis.
Case report
a 58-year-old Japanese man was referred to kurume university Hospital for the treatment of hepatocellular carcinoma (Hcc). Hcv infection had been diagnosed by a positive result for serum Hcv antibody when the patient was 48 years old. at the age of 52, liver cirrhosis was diagnosed. However, the (8) . Prior to admission, the patient's average energy intake had been 2500 kcal/day, with a protein intake of 80 g/day (Fig. 1a) . vital signs were within normal ranges. The patient had peripheral edema, tense ascites and umbilical hernia. laboratory data at admission are summarized in Table ii . The hepatic function of the patient was Figure 1 . (a) laboratory indices for the indicated days after admission. Prior to admission, the patient had a 2500 kcal/day energy and 80 g/day protein intake. after admission, he began nutritional treatment: a 1800 kcal/day energy with 75 g/day protein diet and 50 g of aminoleban ® en (Table i) with abundant Bcaas as a late evening snack. Total energy intake was 2100 kcal/day (32.5 kcal/kg/day) and total protein intake was at least 83.5 g/day (1.3 g/kg/day). at admission, the serum albumin level was 1.79 g/dl. However, this gradually increased and was maintained at ~2.6 g/dl. The serum Bcaa level increased from 365.4 to 450.2 µmol/l, and the BTR increased to 3.65 from 1.70 at admission. (B and C) Computed tomography of abdomen. At admission, severe ascites was noted in the abdomen (B). on day 41, a marked decrease of ascites was noted in a cT scan of the abdomen (c). (d and e) changes in SF-36v2 score after nutritional supplementation as part of the prescribed diet. d shows the actual score on a scale of 0 to 100, and e shows the norm-based score. PF, physical functioning; rP, physical role; BP, bodily pain; gH, general health; vT, vitality; SF, social functioning; re, emotional role; MH, mental health.
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classified as Child-Pugh grade C. Severe ascites and HCC in segment 5 of the liver were noted in computed tomography (cT) images (Fig. 1B) . on admission, serum albumin levels were 1.79 g/dl, and the serum Bcaa to tyrosine ratio (BTr) was 1.70. Therefore, we diagnosed the nutritional status of the patient as protein-energy malnutrition (PeM) with liver cirrhosis. To increase colloid osmotic pressure, a drip infusion of human albumin was administered from day 3 to 5. after the infusion of human albumin, serum albumin levels increased to 2.61 g/dl. in addition, to improve PeM in cirrhosis, 50 g of Bcaa-rich supplementation (aminoleban ® en; Table i ) was provided as a late evening snack. Finally, total energy intake was 2000 kcal/day (32.5 kcal/kg/day) and total protein intake was at least 83.5 g/day (1.3 g/kg/day) (Fig. 1a) . during hospitalization, no significant changes were noted in total energy and protein intake after the administration of Bcaa-rich supplements. However, the patient's edema gradually decreased and disappeared by day 44, while the serum albumin level gradually increased and was maintained at approximately 2.60 g/dl. The serum Bcaa level increased from 365.4 to 450.2 µmol/l. Furthermore, BTR increased to 3.65 from 1.70 at admission (Fig. 1a) . Patient body weight was lower than it had been at admission (Fig. 1B) . Thus, an improvment was seen in nutritional status, and the ascites disappeared by day 41 (Fig. 1c) as indicated by a cT scan. Finally, the Hcc was treated successfully.
The effects of nutritional therapy on the patient's Qol were also evaluated using the Medical outcomes Study 36-item Short-Form Health Survey version 2 (SF-36v2) at admission and on the day of discharge. With nutritional therapy, the patient scores improved: physical functioning (PF) went from 10.0 to 95.0; physical role (Pr) from 0.0 to 100; general health (gH) from 5.0 to 92.0; vitality (vT) from 0.0 to 87.5; social functioning (SF) from 25.0 to 87.5; emotional role (re) from 25.0 to 75.0; mental health (MH) from 10.0 to 65.0 (Fig. 1d) . all the scores showed marked improvement and reached a level that was greater than the Japanese norm-based scores seen with nutritional treatment (Fig. 1e) .
The patient was discharged on day 59 and has continued nutritional therapy with 50 g of Bcaa-rich supplements as a late evening snack. at a 12-month follow-up after discharge, the patient showed no edema or ascites, and had a serum albumin level of 2.39 g/dl, a serum BCAA level of 427.6 µmol/l, and a BTr of 3.78. rBc, red blood cell count; WBc, white blood cell count; aST, aspartate aminotransferase; alT, alanine aminotransferase; ldH, lactate dehydrogenase; alT, alkaline phosphatase; ggT, γ-glutamyltranspeptidase; Bcaa, branched-chain amino acids; BTr, Bcaa to tyrosine ratio; aFP, α-fetoprotein; dcP, des-γ-carboxyprothrombin; HBs-ag, hepatitis B surface antigen; Hcv-ab, hepatitis c antibody.
Discussion
Here, we presented a case suggesting that the administration of Bcaa-rich supplements reduces ascites and improves Qol in patients with liver cirrhosis. Bcaa-rich supplements are commonly used for the treatment of hepatic encephalopathy in patients with liver cirrhosis (3) (4) (5) . in the present case, the administration of Bcaa-rich supplements not only reduced hypoalbuminemia, but also reduced ascites. Bcaa is known to reduce hypoalbuminemia in cirrhotic patients (6, 9) . Previous studies have also reported that Bcaas promote albumin synthesis by improving amino acid imbalance. There are two possible mechanisms behind the ability of Bcaa-rich supplements to reduce hypoalbuminemia. one is that an increased supply of substrate for protein synthesis causes increases in albumin synthesis. However, our patient had had an adequate daily energy and total protein intake prior to admission, and had not had a preference for consuming Bcaa-rich foods, including whey protein and milk products. Fruits, polished rice and refined grains had been included in his daily diet. Thus, the ability of Bcaas to increase the supply of substrate for protein synthesis may increase albumin synthesis. Second, Bcaas facilitate protein synthesis by stimulating the initiation of albumin mrna translation via the activation of intracellular signal transduction systems, particularly systems involving the mammalian target rapamycin (mTor) (10) (11) (12) . For these reasons, Bcaas may increase albumin synthesis and osmotic pressure, which may in turn result in a decrease in extracellular fluid and ascites. one would think that the injection of human albumin might contribute to the increase in serum albumin level. However, previous studies have shown that the half-life of albumin ranges from 5.52 to 11.76 days (13) . in our case, the serum albumin level was maintained for more than 14 days after albumin injection. Therefore, we believe that administration of Bcaa-rich supplements may contribute to reductions in hypoalbuminemia and ascites through an increased supply of substrate for protein and the stimulation of protein synthesis.
in this study, we also showed that Bcaa supplementation improved Qol (14, 15) . in this case, PF, Pr, gH, vT, SF, re and MH scores were significantly lower than the norm-based scores at admission. However, after nutritional treatment, all scores showed marked improvement and reached levels that were above the median for the Japanese population. on the other hand, previous reports showed that Bcaas did not improve the SF-36 score in cirrhotic patients (9, 16, 17) . Three possible mechanisms exist for the improvement in Qol observed in this case. First, marked retention of ascites was noted on admission. in general, the presence of ascites is significantly associated with a poor QOL in cirrhotic patients (18) . as a result of Bcaa-rich supplements, decreased ascites reduced abdominal tension. Thus, a reduction in ascites could be a factor leading to improved SF-36v2 scores. Second, Bcaas act directly on the central nervous system to reduce hepatic encephalopathy (19) . Subclinical hepatic encephalopathy affects mental aspects of Qol (20) . in this case, the elevation of ammonia levels and decreases in BTr suggest that the patient was suffering from subclinical hepatic encephalopathy. Through Bcaa-rich supplements, the ammonia level decreased. Thus, an improvement in subclinical hepatic encephalopathy could be a factor leading to an improvement in SF-36 scores. Third, yamamoto et al reported that cerebral blood flow is decreased in patients with hepatic encephalopathy, and that oral administration of Bcaa increases regional cerebral blood flow (21). In addition, maintenance of adequate cerebral blood flow maintains the QOL (22) . Thus, Bcaas might improve the Qol by maintaining the cerebral blood flow.
in conclusion, we report a case in which Bcaa-rich supplements improved not only ascites, but also Qol in a patient with liver cirrhosis. Thus, Bcaa-rich supplementation may be a new therapeutic agent for cirrhotic patients with ascites.
